At JP Morgan last month, pharmaphorum editor-in-chief Jonah Comstock caught up with Paul Hastings, the CEO of Nkarta, to talk ...

Today, adoption of digital health faces some of the same barriers — scepticism, budget limitations, high expectations, and a ...

US biotech Abcuro has reeled in $200 million in third-round financing that should allow it to complete its pivotal trial of ...

Recognising that challenge, AstraZeneca's rare disease unit Alexion has launched an interactive storybook that can help ...

The EU is the second market for the drug after the US, where it was approved under the Attruby brand name last November, on ...

Stamford, Connecticut-based SpringWorks' Gomekli (mirdametinib) has become the first medicine approved for both adults and children with plexiform neurofibromas (PN) in patients with the genetic ...

Martin, who was appointed as Inspector General for the USAID towards the end of 2023 by former President Joe Biden, was dismissed via an email from Trent Morse, deputy director of the White House ...

Roche's sale of InterMune and Esbriet in the US comes as Boehringer revealed its own follow-up play in the IPF, category, ...

Novartis has agreed to buy Anthos Therapeutics from private equity firm Blackstone for $3.1 billion, adding a drug in ...

This can help individuals feel fuller for longer and can promote weight loss. When measured by traditional weight loss ...

Super Bowl ads aren’t just entertainment; they’re cultural barometers. They reflect what resonates with audiences, what ...

Merck said in a brief statement that discussions are "advanced" but noted that "critical conditions have yet to be met" ...